Medicine
Fosrenol 500 mg chewable tablet
Fosrenol 500 mg chewable tablet is a prescription medicine containing Lanthanum carbonate for oral use, marketed by Takeda Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store FOSRENOL Chewable Tablets and FOSRENOL Oral Powder at 25°C (77°F)…
Key facts
- Active ingredient (INN)
- Lanthanum carbonate
- Brand
- Fosrenol
- Strength
- 500 mg
- Dosage form
- Chewable tablet
- Route
- Oral
- Packs
- 2 bottles
- Marketing authorisation holder
- Takeda Pharmaceuticals
- Manufacturer
- Takeda Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store FOSRENOL Chewable Tablets and FOSRENOL Oral Powder at 25°C (77°F): excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V03AE03 Lanthanum carbonate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 26 October 2004
- Identifiers
- RxCUI 477347, 542465, 602635 +7DailyMed set ID f10776b2-2c25-4343-aabe-68f302e5cb54NDC 54092-252Application NDA021468
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 bottle in 1 package / 45 tablet, chewable in 1 bottle | 54092-252-90 | Takeda Pharmaceuticals | 26 October 2004 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 26 October 2004 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Lanthanum carbonate 500 mg chewable tablet.
Other strengths and forms of Lanthanum carbonate
Clinical summary
Lanthanum carbonate is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). It is available as chewable tablets and oral powder. MedsAcross supplies Lanthanum carbonate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Lanthanum carbonateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Lanthanum carbonate prescribing information (Prasco Laboratories) · U.S. National Library of Medicine, DailyMed
Need Fosrenol 500 mg chewable tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.